Use of systemic glucocorticoids and the risk of colorectal cancer
- PMID: 23116185
- DOI: 10.1111/apt.12115
Use of systemic glucocorticoids and the risk of colorectal cancer
Abstract
Background: Systemic glucocorticoids are potent immunosuppressants, potentially facilitating carcinogenesis. Studies examining glucocorticoids and colorectal cancer risk are few.
Aim: To investigate the association between use of systemic glucocorticoids and colorectal cancer risk, both overall and by cancer stage (localised versus metastatic).
Methods: We conducted a nested population-based case-control study in Northern Denmark (1.8 million people) using medical registries. The study included 14,158 patients with a first-time diagnosis of colorectal cancer from 1991 through 2010. Using risk set sampling, we identified 141,580 population controls, matched on age and gender. Logistic regression models were used to compute odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for covariates.
Results: Frequent use of systemic glucocorticoids (defined as >2 prescriptions) was not associated with overall colorectal cancer risk [adjusted OR (aOR) = 0.93 (95% CI: 0.85-1.00)], compared with never/rare use (≤2 prescriptions). Associations according to duration of use and doses (quartiles of cumulative prednisolone equivalents) were also near the null. Examining colorectal cancer by stage, no substantial associations were found between long-term use (>5 years) of high-dose (>5500 mg) systemic glucocorticoids and localised [aOR = 1.12 (95% CI: 0.81-1.55)] or metastatic [aOR = 0.82 (95% CI: 0.59-1.14)] cancer.
Conclusion: Despite immunological and metabolic effects of frequent use of systemic glucocorticoids, which would be expected to increase colorectal cancer risk, we found no substantial association between the two.
© 2012 Blackwell Publishing Ltd.
Comment in
-
Letter: glucocorticoids use and the risk of colorectal cancer.Aliment Pharmacol Ther. 2013 May;37(10):1026-7. doi: 10.1111/apt.12286. Aliment Pharmacol Ther. 2013. PMID: 23590544 No abstract available.
-
Letter: glucocorticoids use and the risk of colorectal cancer--authors' reply.Aliment Pharmacol Ther. 2013 May;37(10):1027-8. doi: 10.1111/apt.12310. Aliment Pharmacol Ther. 2013. PMID: 23590545 No abstract available.
Similar articles
-
Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study.JAMA Intern Med. 2013 May 13;173(9):743-52. doi: 10.1001/jamainternmed.2013.122. JAMA Intern Med. 2013. PMID: 23546607
-
Use of glucocorticoids and risk of breast cancer: a Danish population-based case-control study.Breast Cancer Res. 2012 Feb 3;14(1):R21. doi: 10.1186/bcr3106. Breast Cancer Res. 2012. PMID: 22305057 Free PMC article.
-
Aspects of survival from colorectal cancer in Denmark.Dan Med J. 2012 Apr;59(4):B4428. Dan Med J. 2012. PMID: 22459726
-
Use of Glucocorticoids and Risk of Community-Acquired Staphylococcus aureus Bacteremia: A Population-Based Case-Control Study.Mayo Clin Proc. 2016 Jul;91(7):873-80. doi: 10.1016/j.mayocp.2016.04.023. Epub 2016 Jun 8. Mayo Clin Proc. 2016. PMID: 27289410
-
Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study.Gastroenterology. 2007 Sep;133(3):755-60. doi: 10.1053/j.gastro.2007.06.014. Epub 2007 Jun 20. Gastroenterology. 2007. PMID: 17678921
Cited by
-
Intestinal epithelial glucocorticoid receptor promotes chronic inflammation-associated colorectal cancer.JCI Insight. 2021 Dec 22;6(24):e151815. doi: 10.1172/jci.insight.151815. JCI Insight. 2021. PMID: 34784298 Free PMC article.
-
Multicystic meningioangiomatosis.BMC Neurol. 2014 Feb 20;14:32. doi: 10.1186/1471-2377-14-32. BMC Neurol. 2014. PMID: 24555776 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
